104 related articles for article (PubMed ID: 35381768)
21. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
[TBL] [Abstract][Full Text] [Related]
22. Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer: tumor heterogeneity should be taken into consideration.
Zhou X; Zhang J; Yun H; Shi R; Wang Y; Wang W; Lagercrantz SB; Mu K
Oncotarget; 2015 Nov; 6(34):36894-902. PubMed ID: 26384297
[TBL] [Abstract][Full Text] [Related]
23. [Influence of the HLDF differentiation factor on the production of cytokines by bio-tissues of breast tissue in its non-malignant diseases and in invasive carcinoma of a non-specific type].
Autenshlyus AI; Studenikina AA; Mikhaylova YS; Proskura AV; Varaksin NA; Sidorov SV; Bogachuk AP; Lipkin VM; Lyakhovich VV
Biomed Khim; 2020 Nov; 66(6):485-493. PubMed ID: 33372907
[TBL] [Abstract][Full Text] [Related]
24. Breast tumour cell subpopulations with expression of the MYC and OCT4 proteins.
Litviakov NV; Bychkov VA; Stakheeva MN; Ibragimova MK; Tsyganov MM; Gaptulbarova KA; Tashireva LA; Bondar LN; Garbukov EY; Slonimskaya EM
J Mol Histol; 2020 Dec; 51(6):717-728. PubMed ID: 33037978
[TBL] [Abstract][Full Text] [Related]
25. PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer.
Ohara AM; Naoi Y; Shimazu K; Kagara N; Shimoda M; Tanei T; Miyake T; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2019 Feb; 173(3):533-543. PubMed ID: 30361874
[TBL] [Abstract][Full Text] [Related]
26. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q
J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107
[TBL] [Abstract][Full Text] [Related]
27. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
28. Intraocular Metastases Secondary to Breast Carcinoma Correlates With Upregulation of Estrogen and Progesterone Receptor Expression in the Primary Tumor.
Parrozzani R; Frizziero L; Testi I; Miglionico G; Perrini P; Pulze S; Pilotto E; Midena E
Invest Ophthalmol Vis Sci; 2016 Aug; 57(10):3944-8. PubMed ID: 27479811
[TBL] [Abstract][Full Text] [Related]
29. The hormone receptor status in breast cancer and the relationship of subtypes with clinicopathological features.
Senel F
Indian J Pathol Microbiol; 2021; 64(4):671-676. PubMed ID: 34673584
[TBL] [Abstract][Full Text] [Related]
30. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
31. Basal vs. luminal A breast cancer subtypes: a matched case-control study using estrogen receptor, progesterone receptor, and HER-2 as surrogate markers.
Ibrahim E; Al-Gahmi AM; Zeenelin AA; Zekri JM; Elkhodary TR; Gaballa HE; Fawzy EE; El sayed ME; Alzahrani MS
Med Oncol; 2009; 26(3):372-8. PubMed ID: 19034706
[TBL] [Abstract][Full Text] [Related]
32. Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases.
Peng L; Zhang Z; Zhao D; Zhao J; Mao F; Sun Q
Pathol Oncol Res; 2021; 27():599894. PubMed ID: 34257555
[No Abstract] [Full Text] [Related]
33. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.
Frogne T; Laenkholm AV; Lyng MB; Henriksen KL; Lykkesfeldt AE
Breast Cancer Res; 2009; 11(1):R11. PubMed ID: 19239686
[TBL] [Abstract][Full Text] [Related]
34. Residual Mammographic Microcalcifications and Enhancing Lesions on MRI After Neoadjuvant Systemic Chemotherapy for Locally Advanced Breast Cancer: Correlation with Histopathologic Residual Tumor Size.
Kim YS; Chang JM; Moon HG; Lee J; Shin SU; Moon WK
Ann Surg Oncol; 2016 Apr; 23(4):1135-42. PubMed ID: 26628432
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Factors for Luminal B-like Breast Cancer.
Ding NH; Liu CF; Hu C; Yuan JQ; Liao WH; Xiao Z
Curr Med Sci; 2019 Jun; 39(3):396-402. PubMed ID: 31209809
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26-30.
Park S; Han Y; Liu Y; Toriola AT; Peterson LL; Colditz GA; Kim SI; Cho YU; Park BW; Park Y
Breast Cancer Res; 2019 Oct; 21(1):110. PubMed ID: 31619259
[TBL] [Abstract][Full Text] [Related]
37. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y
Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
[TBL] [Abstract][Full Text] [Related]
38. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.
De La Cruz LM; Harhay MO; Zhang P; Ugras S
Ann Surg Oncol; 2018 Nov; 25(12):3535-3540. PubMed ID: 29981025
[TBL] [Abstract][Full Text] [Related]
39. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
[TBL] [Abstract][Full Text] [Related]
40. Differential distribution of microRNAs in breast cancer grouped by clinicopathological subtypes.
Li JY; Jia S; Zhang WH; Zhang Y; Kang Y; Li PS
Asian Pac J Cancer Prev; 2013; 14(5):3197-203. PubMed ID: 23803104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]